ADMA Biologics announced that Brian Lenz, executive VP, CFO and general manager, ADMA BioCenters will be transitioning from these positions to a consulting role, effective April 1, 2024. CEO Adam Grossman has been appointed as Interim Chief Financial Officer, effective April 1, 2024. The Company has initiated an executive search for a full-time replacement CFO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ADMA:
- ADMA Biologics Announces CFO Transition
- ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- ADMA Biologics Inc (ADMA) Q4 Earnings Cheat Sheet
- ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- ADMA Biologics Launches ADMAlytics AI Program
